CTSO

SEC source: 0001144204-18-015718 · tv488964_4.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 317,551

F1 · shares: These shares represent restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan").

F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,980 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof, (b) 7,667 of the RSUs granted on June 7, 2016 and unvested as of the date hereof and (c) 38,000 RSUs granted on February 28, 2018 and (iii) 52,904 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-015716 · tv488963_4.xml · derivative · entry 2

Chan Phillip P. · CIK 0001442786 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,750

Underlying: Common Stock · 117,750 shares

Expires 2028-03-15

F3 · derivative.exercise_date: Such options were granted pursuant to the Plan, and shall vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of the Company.

SEC source: 0001144204-18-015716 · tv488963_4.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 440,713

F1 · shares: These shares represent restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan").

F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control," as defined in the Plan: (a) 18,700 RSUs granted on February 24, 2017, (b) 57,000 RSUs granted on June 7, 2016, (c) 130,000 RSUs granted on April 8, 2015, and (d) 10,300 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting:(a) 13,542 of the RSUs granted to the reporting person on February 24, 2017 which are unvested as of the date hereof, (b) 8,667 of the RSUs granted on June 7, 2016 which are unvested as of the date hereof, and (c) 43,000 RSUs granted on February 28, 2018 and (iii) 159,504 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-015453 · tv488826_4.xml · derivative · entry 4

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,920

Underlying: Common Stock · 11,176 shares

Expires 2026-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-015453 · tv488826_4.xml · nonDerivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,070

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

F2 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of the Company, as defined in the Plan: (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016 and (c) 110,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof , (b) 7,000 of the RSUs granted on June 7, 2016 and unvested as of the date hereof, and (c) 34,700 RSUs granted on February 28, 2018 and (iii) 24,732 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-015453 · tv488826_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 261,246

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-015762 · tv488961_4.xml · derivative · entry 2

Mortensen Eric R. · CIK 0001708454 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2028-03-15

F3 · derivative.exercise_date: Such options were granted pursuant to the Plan, and shall vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of the Company.

SEC source: 0001144204-18-015762 · tv488961_4.xml · nonDerivative · entry 1

Mortensen Eric R. · CIK 0001708454 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,500

F1 · shares: These shares represent restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan").

F2 · balance_after: Includes (i) 20,000 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) 14,000 RSUs granted on February 28, 2018, and subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and that will be settled into common stock upon vesting, and (iii) 2,500 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-015764 · tv488962_4.xml · derivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,500

Underlying: Common Stock · 93,500 shares

Expires 2028-03-15

F4 · derivative.exercise_date: Such options were granted pursuant to the Plan, and shall vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of the Company.

SEC source: 0001144204-18-015764 · tv488962_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 258,870

F1 · shares: These shares represent restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan").

F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company: (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof , (b) 7,000 of the RSUs granted on June 7, 2016 and unvested as of the date hereof, and (c) 34,700 RSUs granted on February 28, 2018 and (iii) 24,732 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-022972 · tv492279_4.xml · derivative · entry 2

Kraus Al · CIK 0001368152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,875

Underlying: Common Stock · 28,875 shares

Expires 2028-03-15

F3 · derivative.exercise_date: Such options were granted pursuant to the Plan and vest in four equal parts at the end of each calendar quarter beginning January 1, 2018.

SEC source: 0001144204-18-022972 · tv492279_4.xml · nonDerivative · entry 1

Kraus Al · CIK 0001368152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,046

F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change in Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan").

F2 · balance_after: Includes (a) the following restricted stock units subject to vesting in accordance with the schedule set forth in (1) above: (i) 3,300 restricted stock units granted on March 15, 2018 and reported on this Form 4, (ii) 6,000 restricted stock units granted on February 24, 2017, (iii) 5,000 restricted stock units granted on June 7, 2016, and (iv) 55,000 restricted stock units granted on April 8, 2015, and (b) 55,746 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-022970 · tv492277_4.xml · derivative · entry 2

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,450

Underlying: Common Stock · 14,450 shares

Expires 2028-03-15

F3 · derivative.exercise_date: Such options were granted pursuant to the Plan and vest in four equal parts at the end of each calendar quarter beginning January 1, 2018.

SEC source: 0001144204-18-022970 · tv492277_4.xml · nonDerivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,300

F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change in Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan").

F2 · balance_after: Includes the following restricted stock units subject to vesting in accordance with the schedule set forth in (1) above: (a) 3,300 restricted stock units granted on March 15, 2018 and reported on this Form 4, (b) 6,000 restricted stock units granted on February 24, 2017, (c) 5,000 restricted stock units granted on June 7, 2016, and (d) 55,000 restricted stock units granted on April 8, 2015.

SEC source: 0001144204-18-022969 · tv492276_4.xml · derivative · entry 2

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,450

Underlying: Common Stock · 14,450 shares

Expires 2028-03-15

F3 · derivative.exercise_date: Such options were granted pursuant to the Plan and vest in four equal parts at the end of each calendar quarter beginning January 1, 2018.

SEC source: 0001144204-18-022969 · tv492276_4.xml · nonDerivative · entry 1

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,800

F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change in Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan").

F2 · balance_after: Includes (a) the following restricted stock units subject to vesting in accordance with the schedule set forth in (1) above: (i) 3,300 restricted stock units granted on March 15, 2018 and reported on this Form 4, (ii) 6,000 restricted stock units granted on February 24, 2017, and (iii) 60,000 restricted stock units granted on June 7, 2017, and (b) 4,500 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-022968 · tv492275_4.xml · derivative · entry 2

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,450

Underlying: Common Stock · 14,450 shares

Expires 2028-03-15

F3 · derivative.exercise_date: Such options were granted pursuant to the Plan and vest in four equal parts at the end of each calendar quarter beginning January 1, 2018.

SEC source: 0001144204-18-022968 · tv492275_4.xml · nonDerivative · entry 1

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,800

F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change in Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan").

F2 · balance_after: Includes (a) the following restricted stock units subject to vesting in accordance with the schedule set forth in (1) above: (i) 3,300 restricted stock units granted on March 15, 2018 and reported on this Form 4, (ii) 6,000 restricted stock units granted on February 24, 2017, (iii) 5,000 restricted stock units granted on June 7, 2016, and (iv) 55,000 restricted stock units granted on April 8, 2015, and (b) 2,500 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-014852 · tv488571_4.xml · derivative · entry 4

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,096

Underlying: Common Stock · 1,104 shares

Expires 2026-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-014852 · tv488571_4.xml · nonDerivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,070

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

F2 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of the Company, as defined in the Plan: (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016 and (c) 110,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof , (b) 7,000 of the RSUs granted on June 7, 2016 and unvested as of the date hereof, and (c) 34,700 RSUs granted on February 28, 2018 and (iii) 24,732 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-014852 · tv488571_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 251,174

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-012644 · tv487692_form4.xml · nonDerivative · entry 1

Mortensen Eric R. · CIK 0001708454 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,500

F1 · shares: These shares represent restricted stock units which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes 2,500 shares of common stock owned by the reporting person and 14,000 restricted stock units granted on February 28, 2018 and reported on this Form 4.

SEC source: 0001144204-18-012636 · tv487685_form4.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,250

Underlying: Common Stock · 89,250 shares

Expires 2027-02-24

F1 · derivative.exercise_date: On February 24, 2017, the reporting person was granted an option to purchase 105,000 shares of Common Stock pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"), which was to vest upon achievement of certain performance goals as determined in the discretion of the Compensation Committee of the Board of Directors of CytoSorbents Corporation (the "Company"). This grant was reported on a Form 4 filed on February 28, 2017. On February 28, 2018, the Compensation Committee of the Board of Directors of the Company determined that 85% of such performance criteria was achieved during 2017, resulting in vesting of 89,250 shares underlying this option.

SEC source: 0001144204-18-012636 · tv487685_form4.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 307,451

F2 · shares: These shares represent restricted stock units which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F3 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016 and (c) 125,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,980 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof , (b) 7,667 of the RSUs granted on June 7, 2016 and unvested as of the date hereof and (c) 38,000 RSUs granted on February 28, 2018 and reported on this Form 4 and (iii) 52,904 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-012635 · tv487682_form4.xml · derivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,650

Underlying: Common Stock · 75,650 shares

Expires 2027-02-24

F1 · derivative.exercise_date: On February 24, 2017, the reporting person was granted an option to purchase 89,000 shares of Common Stock pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan ("Plan"), which was to vest upon achievement of certain performance goals as determined in the discretion of the Compensation Committee of the Board of Directors of CytoSorbents Corporation (the "Company"). This grant was reported on a Form 4 filed on February 28, 2017. On February 28, 2018, the Compensation Committee of the Board of Directors of the Company determined that 85% of such performance criteria was achieved during 2017, resulting in vesting of 75,650 shares underlying this option.

SEC source: 0001144204-18-012635 · tv487682_form4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,070

F2 · shares: These shares represent restricted stock units which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F3 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of the Company, as defined in the Plan: (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016 and (c) 110,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof , (b) 7,000 of the RSUs granted on June 7, 2016 and unvested as of the date hereof, and (c) 34,700 RSUs granted on February 28, 2018 and reported on this Form 4 and (iii) 24,732 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-012634 · tv487663_4.xml · derivative · entry 2

Chan Phillip P. · CIK 0001442786 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,200

Underlying: Common Stock · 95,200 shares

Expires 2027-02-24

F1 · derivative.exercise_date: On February 24, 2017, the reporting person was granted an option to purchase 112,000 shares of Common Stock pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"), which was to vest upon achievement of certain performance goals as determined in the discretion of the Compensation Committee of the Board of Directors of CytoSorbents Corporation (the "Company"). This grant was reported on a Form 4 filed on February 28, 2017. On February 28, 2018, the Compensation Committee of the Board of Directors of the Company determined that 85% of such performance criteria was achieved during 2017, resulting in vesting of 95,200 shares underlying this option.

SEC source: 0001144204-18-012634 · tv487663_4.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 430,413

F2 · shares: These shares represent restricted stock units which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F3 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of Company, as defined in the Plan: (a) 18,700 RSUs granted on February 24, 2017, (b) 57,000 RSUs granted on June 7, 2016, and (c) 130,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 13,542 of the RSUs granted to the reporting person on February 24, 2017 which are unvested as of the date hereof, (b) 8,667 of the RSUs granted on June 7, 2016 which are unvested as of the date hereof, and (c) 43,000 RSUs granted on February 28, 2018 and reported on this Form 4 and (iii) 159,504 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-019461 · tv490542_4.xml · derivative · entry 4

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2023-05-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-019461 · tv490542_4.xml · nonDerivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 258,870

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the 2014 Long-Term Incentive Plan (the "Plan"): (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested, (b) 7,000 of the RSUs granted on June 7, 2016 and unvested, and (c) 23,134 RSUs granted on February 28, 2018 and unvested and (iii) 30,607 shares of common stock owned by the reporting person.

F3 · balance_after: Reflects securities owned by the reporting person as of the date of filing of this Form 4.

SEC source: 0001144204-18-019461 · tv490542_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 268,870

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-002684 · tv483558_4.xml · derivative · entry 3

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 44,000 shares

Expires 2018-01-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001144204-18-002684 · tv483558_4.xml · nonDerivative · entry 2

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 283,805

F1 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, and (c) 125,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 35,938 RSUs granted on February 24, 2017 and (b) 23,000 RSUs granted on June 7, 2016, and (iii) 27,967 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-002684 · tv483558_4.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 319,062

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001144204-18-002522 · tv483528_4.xml · derivative · entry 4

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,200

Underlying: Common Stock · 12,400 shares

Expires 2026-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-002522 · tv483528_4.xml · nonDerivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,638

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

F2 · balance_after: Includes (i) the following restricted stock units that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 15,700 restricted stock units granted on February 24, 2017, (b) 47,000 restricted stock units granted on June 7, 2016 and (c) 110,000 restricted stock units granted on April 8, 2015, (ii) the following restricted stock units subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 32,813 restricted stock units granted on February 24, 2017 and (b) 21,000 restricted stock units granted on June 7, 2016 and (iii) 2,125 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-002522 · tv483528_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241,038

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-001799 · tv483029_4.xml · derivative · entry 8

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,600

Underlying: Common Stock · 12,400 shares

Expires 2026-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-001799 · tv483029_4.xml · derivative · entry 7

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2023-05-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-001799 · tv483029_4.xml · nonDerivative · entry 5

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,638

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

F2 · balance_after: Includes (i) the following restricted stock units that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 15,700 restricted stock units granted on February 24, 2017, (b) 47,000 restricted stock units granted on June 7, 2016 and (c) 110,000 restricted stock units granted on April 8, 2015, (ii) the following restricted stock units subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 32,813 restricted stock units granted on February 24, 2017 and (b) 21,000 restricted stock units granted on June 7, 2016 and (iii) 2,125 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-001799 · tv483029_4.xml · nonDerivative · entry 4

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,638

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-001799 · tv483029_4.xml · nonDerivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 251,038

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-001799 · tv483029_4.xml · nonDerivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 261,038

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-001799 · tv483029_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 248,638

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-17-062984 · tv481084_4.xml · derivative · entry 3

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 4,000 shares

Expires 2019-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001144204-17-062984 · tv481084_4.xml · nonDerivative · entry 2

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,062

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, and (c) 125,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 35,938 RSUs granted on February 24, 2017 and (b) 23,000 RSUs granted on June 7, 2016, and (iii) 19,224 shares of common stock owned by the reporting person.

SEC source: 0001144204-17-062984 · tv481084_4.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 271,062

SEC source: 0001144204-17-032195 · v468856_4.xml · nonDerivative · entry 1

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,500

F1 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 6,000 RSUs granted on February 24, 2017 and (b) 60,000 RSUs granted on June 7, 2016 and (ii) 4,500 shares of common stock owned by the reporting person (including 1,500 shares of common stock purchased in the open market on June 9, 2017 and reported on this Form 4).

SEC source: 0001144204-17-032389 · v468859_4.xml · nonDerivative · entry 1

Mortensen Eric R. · CIK 0001708454 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

SEC source: 0001144204-17-031786 · v468721_4.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,062

F1 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, and (c) 125,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 35,938 RSUs granted on February 24, 2017 and (b) 23,000 RSUs granted on June 7, 2016 and (iii) 19,224 shares of common stock owned by the reporting person (including 2,500 shares of common stock purchased in the open market on June 8, 2017 and reported on this Form 4).